PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
 
J Exp Med. 1995 July 1; 182(1): 67–74.
PMCID: PMC2192096

GD2 oligosaccharide: target for cytotoxic T lymphocytes

Abstract

Carbohydrate antigens rarely provide target epitopes for cytotoxic T lymphocytes (CTL). Disialoganglioside GD2 is a glycolipid expressed at high levels in human tumors and a small group of murine lymphomas (EL4, RBL5, RMA, RMA-S, A13, and BALBRVE). Immunization of C57B1/6 mice with irradiated EL4 cells stimulated a specific CTL response and protected these animals from engraftment of EL4 lymphoma. The CTL activity resided in the CD4-CD8+ population, was dependent on T cell receptor alpha/beta, and was not removed by anti-natural killer cell immunoabsorption, but was restricted to GD2 and H-2b bearing targets. CTL activity could be completely inhibited by GD2-oligosaccharide- specific monoclonal antibodies and their F(ab')2 fragments, but not by immunoglobulin G3 myelomas or antibodies against GD3 or GM2. Soluble GD2 did not inhibit specific tumor lysis. RMA-S lymphoma cells (GD2+H- 2b-TAP2 deficient) were resistant to GD2-specific CTL. Sialic acid- containing peptides eluted from EL4 lymphoma cells could (a) stabilize H-2 molecules on RMA-S cells and (b) sensitize them for GD2-specific CTL. Control peptides (derived from vesicular stomatitis virus nucleoprotein peptide and GD2-negative lymphomas) could also stabilize H-2 on RMA-S, but were resistant to GD2-specific CTL. These H-2-binding peptides could be purified by anti-GD2 affinity chromatography. We postulate a new class of naturally occurring epitopes for T cells where branched-chain oligosaccharides are linked to peptides with anchoring motifs for the major histocompatibility complex class I pocket. While analogous to the haptens trinitrophenyl and O-beta-linked acetyl- glucosamine, the potential implications of natural carbohydrates as antigenic epitopes for CTL in biology are considerable.

Full Text

The Full Text of this article is available as a PDF (747K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol. 1992;52:1–123. [PubMed]
  • Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992 Dec 24;71(7):1093–1102. [PubMed]
  • Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol. 1992 Jul 15;149(2):380–388. [PubMed]
  • Martin S, von Bonin A, Fessler C, Pflugfelder U, Weltzien HU. Structural complexity of antigenic determinants for class I MHC-restricted, hapten-specific T cells. Two qualitatively differing types of H-2Kb-restricted TNP epitopes. J Immunol. 1993 Jul 15;151(2):678–687. [PubMed]
  • Ono K, Takahashi K, Hirabayashi Y, Itoh T, Hiraga Y, Taniguchi M. Mouse melanoma antigen recognized by Lyt-2- and L3T4- cytotoxic T-lymphocytes. Cancer Res. 1988 May 15;48(10):2730–2733. [PubMed]
  • Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, Elliott T. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med. 1994 Aug 1;180(2):739–744. [PMC free article] [PubMed]
  • Ljunggren HG, Päbo S, Cochet M, Kling G, Kourilsky P, Kärre K. Molecular analysis of H-2-deficient lymphoma lines. Distinct defects in biosynthesis and association of MHC class I heavy chains and beta 2-microglobulin observed in cells with increased sensitivity to NK cell lysis. J Immunol. 1989 Apr 15;142(8):2911–2917. [PubMed]
  • Ye JN, Cheung NK. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. Int J Cancer. 1992 Jan 21;50(2):197–201. [PubMed]
  • Cheung NK, Walter EI, Smith-Mensah WH, Ratnoff WD, Tykocinski ML, Medof ME. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988 Apr;81(4):1122–1128. [PMC free article] [PubMed]
  • Cheung NK, Canete A, Cheung IY, Ye JN, Liu C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer. 1993 May 28;54(3):499–505. [PubMed]
  • Ohlén C, Bastin J, Ljunggren HG, Foster L, Wolpert E, Klein G, Townsend AR, Kärre K. Resistance to H-2-restricted but not to allo-H2-specific graft and cytotoxic T lymphocyte responses in lymphoma mutant. J Immunol. 1990 Jul 1;145(1):52–58. [PubMed]
  • Bernhard H, Karbach J, Strittmatter W, Meyer zum Büschenfelde KH, Knuth A. Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. Int J Cancer. 1993 Sep 30;55(3):465–470. [PubMed]
  • Fukuta S, Werkmeister JA, Burns GF, Ginsburg V, Magnani JL. Monoclonal antibody Leo Mel 3, which inhibits killing of human melanoma cells by anomalous killer cells, binds to a sugar sequence in GD2 (II3(NeuAc)2-GgOse3Cer) and several other gangliosides. J Biol Chem. 1987 Apr 5;262(10):4800–4803. [PubMed]
  • Galetto G, Law LW, Rogers MJ. The Rauscher-MuLV-induced leukemia, RBL-5, bears two tumor-associated transplantation antigens expressed on distinct molecules. Int J Cancer. 1985 Dec 15;36(6):713–719. [PubMed]
  • Franksson L, Petersson M, Kiessling R, Kärre K. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur J Immunol. 1993 Oct;23(10):2606–2613. [PubMed]
  • von Bonin A, Martin S, Plaga S, Hebbelmann S, Weltzien HU. Purified MHC class I molecules present hapten-conjugated peptides to TNP/H-2Kb-specific T cell hybridomas. Immunol Lett. 1993 Jan;35(1):63–68. [PubMed]
  • von Bonin A, Ortmann B, Martin S, Weltzien HU. Peptide-conjugated hapten groups are the major antigenic determinants for trinitrophenyl-specific cytotoxic T cells. Int Immunol. 1992 Aug;4(8):869–874. [PubMed]
  • Takahashi K, Ono K, Hirabayashi Y, Taniguchi M. Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol. 1988 May 1;140(9):3244–3248. [PubMed]
  • Hersey P, MacDonald M, Werkman H. Western blot analysis of antigens on melanoma cells recognized by cytotoxic T cells. J Natl Cancer Inst. 1988 Aug 3;80(11):826–835. [PubMed]
  • Grooten J, Leroux-Roels G, Fiers W. Specific suppression elicited by EL4 lymphoma cells in syngeneic mice. Specificity includes self-antigens on EL4. Eur J Immunol. 1987 May;17(5):605–611. [PubMed]
  • Fitch FW, McKisic MD, Lancki DW, Gajewski TF. Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol. 1993;11:29–48. [PubMed]
  • Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, Cheung NK. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987 Oct 15;47(20):5377–5381. [PubMed]
  • Chang HR, Cordon-Cardo C, Houghton AN, Cheung NK, Brennan MF. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer. 1992 Aug 1;70(3):633–638. [PubMed]
  • Longee DC, Wikstrand CJ, Månsson JE, He X, Fuller GN, Bigner SH, Fredman P, Svennerholm L, Bigner DD. Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas. Acta Neuropathol. 1991;82(1):45–54. [PubMed]
  • Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629–7633. [PubMed]
  • Saarinen UM, Sariola H, Hovi L. Recurrent disseminated retinoblastoma treated by high-dose chemotherapy, total body irradiation, and autologous bone marrow rescue. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):315–319. [PubMed]
  • van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643–1647. [PubMed]
  • Evans A, Main E, Zier K, Ikegaki N, Tartaglione M, Kennett R, Lampson L. The effects of gamma interferon on the natural killer and tumor cells of children with neuroblastoma. A preliminary report. Cancer. 1989 Oct 1;64(7):1383–1387. [PubMed]
  • Sabzevari H, Reisfeld RA. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. Cancer Res. 1993 Oct 15;53(20):4933–4937. [PubMed]
  • Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol. 1993 Oct 1;151(7):3693–3703. [PubMed]
  • Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992 Nov 1;176(5):1453–1457. [PMC free article] [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press